Abstract: An HIV-coinfected patient presented the rtM204V/I-rtL180M double resistance mutation in serum and DBS.
Result: One patient had the double resistance polymerase mutation rtM204V/I-rtL180M, in both serum and DBS.
Discussion: Regarding resistance mutations, the double rtM204V/I-rtL180M mutation in polymerase gene (to lamivudine, telbivudine and entecavir:partial) was observed in both serum and DBS samples from an HIV-treated patient.
Identification and Characterization of Besifovir-Resistant Hepatitis B Virus Isolated from a Chronic Hepatitis B Patient.
Result: This phenomenon is consistent with previous report, demonstrating that the rtL180M mutation in HBV polymerase is commonly accompanied by rtM204V or rtM204I mutations.
Discussion: This assay is relative not sensitive compared to our cloning and sequencing analysis, and cannot discriminate whether the two rtM204V and rtM204I mutations are separately or simultaneously exist in the same HBV genome.
Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy.
Abstract: The most frequently encountered RAMs are M204V/I: 48.8%, L180M: 33.3%, L80V: 28.8%, and V173L: 42.2%.
Result: M204V/I: 48.8%, plus L180M: 33.3% +- L80V: 28.8% and V173L: 42.2%:a profile suggestive for LAM resistance (with all mutations, except for M204V, also being associated with telbivudine resistance, and the combination of L180M, M204V, andV173L being associated with entecavir (ETV) resistance.
Discussion: In our study, despite the frequent association of the primary resistance mutations M204V/I with the compensatory
Rapid Turnover of Hepatitis B Virus Covalently Closed Circular DNA Indicated by Monitoring Emergence and Reversion of Signature-Mutation in Treated Chronic Hepatitis B Patients.
Abstract: APPROACH AND RESULTS: In this study, we retrospectively monitored the emergence and reversion of the rtM204I/V mutant, a signature lamivudine resistance (LAMR ) mutation serving as a biomarker of cccDNA turnover in liver biopsies and longitudinal serum samples from two clinical trials.
Method: Percentage Composition of rtM204I/V in HBV cccDNA, Viral DNA, and RNA.
Method: Percentages of rtM204I/V mutations were calculated using Sequencher software (Gene Codes, Ann Arbor, MI).
Method: To exclude the potential impact of adefovir on the evolution of drug resistance mutation, only those patients from the MONO group who developed the signature rtM204I/V mutation durin
Prevalence and characteristics of hepatitis B and D virus infections among HIV-positive individuals in Southwestern Nigeria.
Abstract: HBV DRMs V173L, L180M, S202I and M204V/I, which are associated with lamivudine resistance, were detected in 32.2% (n = 10/31) of the HBV DNA-positive samples.
Result: Amino acid substitutions were detected in the following frequency: rtM204V/I (9/31; 29.0%), rtL180M (8/31; 25.8%), rtV173L (7/31; 22.5%).
Result: No single mutation was detected while all amino acid substitutions were detected in combinations as rtL180M + rtV173L + rt
Virologic analysis of tenofovir resistance in a patient with chronic hepatitis B experiencing viral breakthrough during combination treatment with tenofovir disoproxil fumarate and entecavir.
Abstract: A recent Korean report showed that two patients with viral breakthrough during treatment with TDF-containing regimens were found to carry five reverse transcriptase (rt) mutations ([rt]S106C[C], rtH126Y[Y], rtD134E[E], rtM204I/V, and rtL269I [I]), with the C, Y, E, and I mutations being associated with tenofovir resistance.
The Occurrence of rtA194T Mutant After Long-Term Lamivudine Monotherapy Remains Sensitive to Tenofovir Disoproxil Fumarate: A Case Report.
Discussion: Three mutations associated with LAM resistance have been mostly described: rtM204V/I in C domain, rtV173L and rtL180M in B domain.
rt269I Type of Hepatitis B Virus (HBV) Polymerase versus rt269L Is More Prone to Mutations within HBV Genome in Chronic Patients Infected with Genotype C2: Evidence from Analysis of Full HBV Genotype C2 Genome.
Abstract: We also found that there are a total of 19 signature single nucleotide polymorphisms (SNPs), of which 2 and 17 nonsynonymous mutation types were specific to rt269L and rt269I, respectively: Of these, most are HBeAg negative infections (preC-W28*, X-V5M and V131I), lowered HBV DNA or virion production (C-I97F/L, rtM204I/V) or preexisting nucleot(s)ide analog resistance (NAr) (rtN139K/H, rtM204I/V and
Global prevalence and phylogeny of hepatitis B virus (HBV) drug and vaccine resistance mutations.
Abstract: RAM M204I/V had the highest prevalence, occurring in 3.8% (109/2838) of all HBV sequences in our data set, and a significantly higher rate in genotype C at 5.4% (60/1102, p = 0.0007).
Method: ETV resistance: Two or more amino acid substitutions are required across the HBV RT protein to confer resistance to ETV which could occur as a combination of M204I/V with one or more of the following substitutions L80I/V, I163V, I169T, V173L, L180M, A181S/T/V, T184X, A186T, S202C/G/I/R, M250I/V
HBV mutation literature information.
PMID: 
2022
Scientific reports
Browser Board
Co-occurred Entities
Filtrator
ViMRT